‘Neutral’ rating for Calliditas Therapeutics AB (publ) (CALT) confirmed by Citigroup

Citigroup maintained its neutral rating on the company’s shares Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Free Report) in a report published on Friday, Benzinga reports. The current target price for the company’s stock is $39.00.

Several other research analysts have also commented on the company recently. Jefferies Financial Group reiterated a hold rating and set a $39.00 price target (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday. In a research report on Tuesday, Stifel Nicolaus reiterated a hold rating and set a price target of $40.00 (down from $55.00) on shares of Calliditas Therapeutics AB (publ). HC Wainwright reissued a Neutral rating and set a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday. Finally, in Tuesday’s research report, Lifesci Capital downgraded Calliditas Therapeutics AB (publ) from a “buy” rating to a “hold” rating. Six investment analysts have rated the stock with a hold rating. According to MarketBeat.com, the stock currently has a consensus rating of Hold and an average price target of $35.00.

Download our latest stock report on CALT

Calliditas Therapeutics AB (publ) turnover increase by 3.9%

Shares of Calliditas Therapeutics AB (publ) opened at $39.99 on Friday. The stock has a fifty-day simple moving average of $21.99 and a 200-day simple moving average of $21.81. Calliditas Therapeutics AB has a 12 month low of $15.25 and a 12 month high of $40.00. The company’s market capitalization is $1.19 billion, its P/E ratio is -21.62 and its beta is 1.50. The company has a current ratio of 2.69, a quick ratio of 2.62 and a debt to equity ratio of 8.46.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) last announced its quarterly earnings results on Thursday, May 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.74). Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. The company’s revenue for the quarter was $28.43 million, compared to the consensus estimate of $35.78 million. Sell-side analysts predict that Calliditas Therapeutics AB will post -0.41 earnings per share for the current fiscal year.

Institutional Trading Calliditas Therapeutics AB (publ)

A hedge fund recently bought new shares of Calliditas Therapeutics AB (publ). Optiver Holding BV acquired a new position in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. An institutional investor purchased 980 shares of the company’s stock worth approximately $25,000. 2.83% of the shares are held by institutional investors and hedge funds.

About Calliditas Therapeutics AB (publ)

(Get the free report)

Calliditas Therapeutics AB (publ), a commercial-stage biopharmaceutical company focused on identifying, developing and commercializing novel therapeutics in orphan drug indications, with a focus on kidney and liver diseases, which have significant unmet medical need in the United States both Europe and Asia.

Featured Stories

Get Calliditas Therapeutics AB (publ) news and ratings every day. – Enter your email address below to receive a daily concise summary of the latest news and analyst ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com’s FREE daily email newsletter.